Home » Posts tagged with » Solid tumors
Seattle Genetics signs $4.4bn worth oncology deals with Merck

Seattle Genetics signs $4.4bn worth oncology deals with Merck

US biotech company Seattle Genetics has secured deals worth up to $4.4 billion with Merck, that include two new strategic oncology collaborations. The two major pharma companies will develop and commercialize Seattle Genetics’ ladiratuzumab vedotin across the world. Ladiratuzumab vedotin is an investigational antibody-drug conjugate (ADC) that targets LIV-1, which is presently in phase 2 […]

Blueprint Medicines strikes $1.7bn worth deal with Roche for pralsetinib

Swiss pharma giant Roche and US precision therapy company Blueprint Medicines have entered into a worldwide licensing and collaboration deal potentially worth up to $1.703 billion for the latter’s cancer drug candidate pralsetinib. Through the deal, Roche gains exclusive rights for the co-development and marketing of the investigational drug for RET-altered cancers across the world […]

Continue reading …
Unum Therapeutics acquires kinase inhibitors developer Kiq

Unum Therapeutics, a US biopharma company, has acquired Kiq, a biotech company focused on the discovery and development of precision kinase inhibitors, in an all-stock deal. Focused on developing therapies for solid tumors, Unum Therapeutics, through the deal gains access to a clinical-stage compound called PLX9486, which is a selective KIT D816V inhibitor. PLX9486 will […]

Continue reading …
TScan, Novartis to develop T cell receptor therapies for solid tumors

TScan Therapeutics has partnered with Swiss pharma giant Novartis to discover and develop novel TCR-engineered T cell receptor therapies for the treatment of solid tumors using the former’s TScan Discovery Platform. The TScan platform will be used for discovering novel cancer antigens that can be targeted by TCR-based therapies. TScan Therapeutics will be engaged in […]

Continue reading …
Merck acquires ArQule for $2.7bn to further diversify oncology pipeline

Merck acquisition of ArQule : Merck has completed its previously announced acquisition of ArQule for $20 per share or about $2.7 billion as per the latest pharma acquisition news. The pharma giant announced the deal in December 2019 in a move to further diversify its oncology pipeline with the Massachusetts-based ArQule focused on developing kinase […]

Continue reading …
PACT Pharma raises $75m to develop neoTCR-T cell therapies for solid tumors

PACT Pharma, a California-based clinical stage company, which is focused on developing fully personalized neoTCR-T cell therapies for solid tumors, has raised $75 million in a Series C financing round. The funding round was led by Vida Ventures, a life science venture firm, with participation from the current investors of PACT Pharma. The clinical stage […]

Continue reading …
Amgen to take 20.5% stake in Chinese biotech company BeiGene for $2.7bn

US biopharma company Amgen has signed an all-cash deal to acquire a 20.5% stake in Chinese biotech company BeiGene for about $2.7 billion, as per the latest pharma acquisition news. The Beijing-based BeiGene is a research-based, oncology-focused biotechnology company, which is engaged in developing molecularly targeted and immuno-oncology drug candidates for cancer treatment. The transaction […]

Continue reading …
JAVELIN Medley trial : First patient dosed with BAVENCIO, CMP-001 combo

Checkmate Pharmaceuticals announced the dosing of the first patient in a phase 1b/2 study of BAVENCIO (avelumab) in multi-drug combinations with its lead candidate CMP-001 in patients having squamous cell cancer of the head and neck (SCCHN), as part of the JAVELIN Medley trial. CMP‐001 is a C0pG‐A Toll‐like receptor 9 (TLR9) agonist that is […]

Continue reading …
Amphivena Therapeutics raises $62m to advance AMV564 into solid tumors

Amphivena Therapeutics funding round : Amphivena Therapeutics has raised $62 million in a Series C financing round to expand the clinical development of its lead candidate AMV564 into solid tumors and also to develop its T cell engagement portfolio. Based in California, Amphivena Therapeutics is a clinical-stage immuno-oncology company focused on developing T cell engager […]

Continue reading …